MOLECULAR INSIGHT PHARMACEUTICALS, INC.
- Country
- 🇺🇸United States
- Ownership
- Private, Subsidiary
- Established
- 1997-01-01
- Employees
- 71
- Market Cap
- -
- Website
- http://molecularinsight.com
Clinical Trials
24
Trial Phases
3 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (18 trials with phase data)• Click on a phase to view related trials
Expanded Access Program of Ultratrace Iobenguane I131 for Malignant Relapsed/Refractory Pheochromocytoma/Paraganglioma
- Conditions
- ParagangliomaPheochromocytoma
- First Posted Date
- 2016-11-11
- Last Posted Date
- 2019-01-30
- Lead Sponsor
- Molecular Insight Pharmaceuticals, Inc.
- Registration Number
- NCT02961491
- Locations
- 🇺🇸
University of Iowa, Iowa City, Iowa, United States
🇺🇸Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States
🇺🇸MD Anderson Cancer Center, Houston, Texas, United States
Study to Evaluate 99mTc-MIP-1404 SPECT/CT Imaging in Men With Biopsy Proven Low-Grade Prostate Cancer
- Conditions
- Prostate Cancer
- Interventions
- Drug: 99mTc-MIP-1404 InjectionDiagnostic Test: Whole-Body Planar and pelvic SPECT/CT scan
- First Posted Date
- 2015-11-25
- Last Posted Date
- 2019-04-10
- Lead Sponsor
- Molecular Insight Pharmaceuticals, Inc.
- Target Recruit Count
- 531
- Registration Number
- NCT02615067
- Locations
- 🇺🇸
City of Hope Cancer Center, Duarte, California, United States
🇺🇸VA Greater Los Angeles Healthcare, Los Angeles, California, United States
🇺🇸University of California, Los Angeles, Los Angeles, California, United States
A Phase 2 Study With MIP-1404 in Men With High-Risk PC Scheduled for RP and EPLND Compared to Histopathology
- Conditions
- Prostate Cancer
- First Posted Date
- 2012-08-17
- Last Posted Date
- 2017-02-07
- Lead Sponsor
- Molecular Insight Pharmaceuticals, Inc.
- Target Recruit Count
- 105
- Registration Number
- NCT01667536
- Locations
- 🇺🇸
City of Hope National Cancer Center, Duarte, California, United States
🇺🇸Mayo Clinic, Rochester, Minnesota, United States
🇺🇸New York Presbyterian Hospital - Cornell, New York City, New York, United States
99mTc-MIP-1404 for Imaging Prostate Cancer: Phase I Clinical Study to Assess the Image Quality of a Simplified Kit Formulation Compared to a Multi-step Preparation of 99mTc-MIP-1404
- First Posted Date
- 2012-08-01
- Last Posted Date
- 2015-11-25
- Lead Sponsor
- Molecular Insight Pharmaceuticals, Inc.
- Target Recruit Count
- 6
- Registration Number
- NCT01654874
- Locations
- 🇺🇸
New York Presbyterian Hospital, Weill Cornell Medical College, New York, New York, United States
A Phase 1 Pilot Study of 99mTc-MIP-1404 SPECT/CT Imaging to Histology in Men With Prostate Cancer
- Conditions
- Prostate Cancer
- Interventions
- Drug: 99mTc MIP 1404
- First Posted Date
- 2012-06-08
- Last Posted Date
- 2015-11-25
- Lead Sponsor
- Molecular Insight Pharmaceuticals, Inc.
- Target Recruit Count
- 9
- Registration Number
- NCT01615406
- Locations
- 🇺🇸
The University of Texas Health Science Center - Houston, Houston, Texas, United States
- Prev
- 1
- 2
- 3
- 4
- Next